Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

BearDownAZ

Aug 06, 2019 08:37AM

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

noretreat

Aug 06, 2019 09:11AM

RVXoldtimer

Rank: President [?]

Points: 3190 [?]

Votes: 23 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

in response to

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

noretreat

posted on Aug 06, 2019 10:49AM

Major setback! We have been set up for the last year for a sale but are now just where RVX was many years ago. It will take many years and raising a lot more cash probably to get anywhere.

4 Recommendations

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

Nextblockbuster

Aug 06, 2019 11:32AM

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

BearDownAZ

Aug 06, 2019 12:39PM

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

RVXoldtimer

Aug 06, 2019 01:20PM

Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

noretreat